Latest News

M&As this week: Evotec, BioreclamationIVT

German pharmaceutical research company Evotec has acquired US-based drug discovery and development company Aptuit for...

M&As this week: Evotec, BioreclamationIVT

TRACON Pharmaceuticals reports positive results from Phase Ib/II trial of HCC drug

TRACON Pharmaceuticals has reported positive results from the National Cancer Institute (NCI) Phase Ib/II clinical trial of TRC105 and Nexavar (sorafenib) to treat patients with...

TRACON Pharmaceuticals reports positive results from Phase Ib/II trial of HCC drug

Amgen’s EBBINGHAUS trial of Repatha shows favourable outcome

Amgen’s EBBINGHAUS trial of Repatha shows favourable outcome

Deals this week: NicOx, FibroGen, Omeros

NicOx has announced the private placement of 3.5 million new ordinary shares priced at €7.5 ($8.85) each to raise €26.25m ($30.97m) in...

Deals this week: NicOx, FibroGen, Omeros

Lexicon announces additional positive Phase III data for diabetes drug

Lexicon Pharmaceuticals has reported additional positive data from its Phase III inTandem2 clinical trial of sotagliflozin in adult type 1 diabetes patients on a background of optimised insulin. ...

Lexicon announces additional positive Phase III data for diabetes drug

Achieve begins cytisine’s clinical programme for smoking cessation

Achieve Life Sciences has initiated the Cytisine Clinical Development Programme in the US to evaluate the product candidate as a form of treatment for smoking...

Achieve begins cytisine’s clinical programme for smoking cessation

Iovance commences LN-145 dosing in Phase II trial for cervical cancer

Iovance commences LN-145 dosing in Phase II trial for cervical cancer

Researchers demonstrate use of breast cancer drug to shrink brain tumours

Researchers from the University of Queensland’s Institute for Molecular Bioscience in Australia and the Fred Hutchinson Cancer Research Centre in the US have conducted a clinical trial to...

Researchers demonstrate use of breast cancer drug to shrink brain tumours

BMS Phase III’s combination trial for RCC meets one co-primary endpoint

Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or...

BMS Phase III’s combination trial for RCC meets one co-primary endpoint

Vyriad and Sanford Health begin Phase I viro-immunotherapy trial

US-based biopharmaceutical firm Vyriad has initiated a clinical trial at integrated health system Sanford Health to evaluate a genetically engineered virus for destroying therapy-resistant tumours. ...

Vyriad and Sanford Health begin Phase I viro-immunotherapy trial

University of Southampton investigates Acerta’s lymphoma drug

University of Southampton investigates Acerta’s lymphoma drug

PCI Biotech starts dosing in Phase I extension study for bile duct cancer

Norwegian biopharmaceutical firm PCI Biotech has started dosing patients in a Phase I extension study with fimaCHEM to treat inoperable perihilar bile duct...

PCI Biotech starts dosing in Phase I extension study for bile duct cancer

Viamet reports positive Phase II data for vulvovaginal candidiasis drug

Viamet Pharmaceuticals has reported positive results from a Phase II clinical trial (REVIVE) of VT-1161 to treat recurrent vulvovaginal candidiasis (RVVC)...

Viamet reports positive Phase II data for vulvovaginal candidiasis drug

Chiasma and FDA agree on new Phase III trial design for acromegaly drug

The US Food and Drug Administration (FDA) has agreed on biopharmaceutical firm Chiasma’s new Phase III clinical trial (OPTIMAL) design to evaluate its octreotide capsules product candidate...

Chiasma and FDA agree on new Phase III trial design for acromegaly drug

Cyclodextrin slows NPC progression in new Washington University trial

Cyclodextrin slows NPC progression in new Washington University trial

Deals this week: HitGen, Calithera Biosciences, Esperion Therapeutics

HitGen has signed an agreement with LEO Pharma to use its advanced technology platform to discover new small...

Deals this week: HitGen, Calithera Biosciences, Esperion Therapeutics

UK researchers report positive data from new diabetes trial

UK researchers report positive data from new diabetes trial

M&As this week: SELLAS Life Sciences Group, Cempra

SELLAS Life Sciences Group has signed a definitive agreement to merge with Galena...

M&As this week: SELLAS Life Sciences Group, Cempra

Immunicum starts enrolment in US for Phase II oncology trial

Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell...

Immunicum starts enrolment in US for Phase II oncology trial

Biotecnol and Cancer Research UK to assess Tb535H for solid tumours

Immune-oncology firm Biotecnol and Cancer Research UK have entered a collaboration agreement to evaluate Tb535H in clinical trials to treat patients suffering from solid...

Biotecnol and Cancer Research UK to assess Tb535H for solid tumours

WIN Consortium to conduct targeted tri-therapy trial for NSCLC

French non-profit healthcare network WIN Consortium (WIN) is set to conduct a clinical trial (SPRING) of a new three targeted therapies combination as first-line treatment for patients...

WIN Consortium to conduct targeted tri-therapy trial for NSCLC
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_1016278895